Welcome to our dedicated page for OMADA HEALTH SEC filings (Ticker: OMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Omada Health, Inc. (Nasdaq: OMDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a virtual-first, between-visit healthcare provider focused on cardiometabolic and musculoskeletal conditions, Omada uses these filings to report on its financial condition, operations, and material events related to its digital chronic care platform.
Investors can review current reports on Form 8-K, which Omada uses to furnish press releases announcing quarterly results and other significant developments. For example, recent 8-K filings reference earnings press releases for periods in which the company reported revenue, member growth, and updates on its GLP-1-related offerings and AI capabilities. These current reports help readers connect headline financial and operational metrics to the underlying SEC record.
In addition to 8-Ks, Omada’s periodic reports on Form 10-Q and Form 10-K (accessible through the SEC and linked from this page when available) typically contain more detailed information on revenue composition, cost structure, research and development spending, and risks associated with its virtual care and GLP-1 programs. These filings are particularly relevant for understanding how Omada’s cardiometabolic and musculoskeletal programs, GLP-1 Care Tracks, and prescribing and medication management capabilities are reflected in its financial statements and risk disclosures.
Stock Titan enhances this information with AI-powered summaries that explain key points from lengthy filings, helping readers quickly identify sections related to Omada’s chronic care model, GLP-1 initiatives, and digital health operations. Users can also monitor updates to OMDA’s filings in near real time, including new 8-Ks, 10-Qs, 10-Ks, and other relevant forms, to follow how the company reports on its performance and material events over time.
Omada Health, Inc. director Trevor Fetter reported an equity award and updated holdings. He received 10,882 shares of Common Stock as a grant, represented by restricted stock units (RSUs) with a grant price of $0.00 per share. Each RSU converts into one share upon vesting.
According to the footnotes, 100% of these RSUs will vest on the earlier of the first anniversary of the grant date or the date of the 2027 Annual Meeting of Omada Health stockholders, subject to his continued service. Following the award, he directly holds 23,533 shares and indirectly holds 111,200 shares through a family trust where he is a trustee and beneficiary.
Omada Health, Inc. director Jeryl L. Hilleman received an equity grant in the form of restricted stock units. The award covers 10,882 shares of Common Stock, with no cash paid per share. After this grant, Hilleman directly holds 25,220 shares.
The RSUs convert into one share of Common Stock each as they vest. According to the terms, 100% of the RSUs vest on the earlier of the first anniversary of the grant date or the date of the company’s 2027 Annual Meeting of stockholders, subject to continued service through that date.
Stavisky Adam reported acquisition or exercise transactions in this Form 4 filing.
Omada Health, Inc. director Adam Stavisky reported receiving a grant of 10,882 restricted stock units (RSUs), each convertible into one share of Common Stock at no cost when vested.
All RSUs vest 100% on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting, subject to continued service, bringing his direct holdings to 20,618 shares.
Omada Health, Inc. director Jonathan D. Root received a grant of 10,882 restricted stock units, representing a stock-based compensation award with no cash purchase price. These RSUs convert into one share of common stock each upon vesting, with all units vesting on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of stockholders, subject to continued service. Following this grant, Root holds 191,057 shares of common stock.
Klapstein Julie D reported acquisition or exercise transactions in this Form 4 filing.
Omada Health, Inc. director Julie D. Klapstein received a grant of 10,882 restricted stock units, each representing one share of Common Stock at no purchase price. Following this award, she holds 21,316 shares directly. The RSUs vest 100% on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of stockholders, subject to continued service.
Omada Health, Inc. director Anne Beal received a grant of 10,882 shares of Common Stock in the form of restricted stock units (RSUs). The RSUs have no cash exercise price and will convert into one share of Common Stock per unit when they vest.
According to the award terms, 100% of the RSUs will vest on the earlier of the first anniversary of the grant date or the date of the 2027 Annual Meeting of stockholders, if she continues in service through that date. After this grant, Beal directly holds 20,618 shares of Omada Health common stock.
Jain Sachin H. reported acquisition or exercise transactions in this Form 4 filing.
Omada Health, Inc. director Sachin H. Jain received a grant of 10,882 restricted stock units, each convertible into one share of Common Stock upon vesting. After this award, he holds 20,618 shares of Common Stock directly. The RSUs vest 100% on the earlier of the first anniversary of the grant date or the date of Omada Health’s 2027 Annual Meeting of stockholders, contingent on his continued service through that vesting date.
Omada Health, Inc. Chief Executive Officer Sean P. Duffy reported an open-market sale of 14,960 shares of common stock on June 16, 2026 at an average price of $17.3604 per share. The transaction was made pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026, indicating it was pre-scheduled.
Following the sale, Duffy directly holds 411,861 shares of Omada Health common stock. In addition, 851,659 shares are held indirectly in family trusts for the benefit of his family members, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Omada Health, Inc. Chief Financial Officer Steven L. Cook sold 6,800 shares of common stock in an open-market transaction. The sale took place on June 15, 2026 at a weighted average price of $17.2329 per share, based on multiple trades between $17.00 and $17.47.
The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan that Cook adopted on March 14, 2026, indicating it was scheduled in advance rather than timed discretionarily. Following this sale, he directly holds 187,209 shares of Omada Health common stock.
Omada Health, Inc. Chief Accounting Officer Gracey Craig sold 6,894 shares of Common Stock on June 12, 2026 in an open-market transaction at a weighted average price of $17.4243 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026. Following this transaction, Craig directly owns 9,191 Omada Health shares.